Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Tabu, Kouichi ^a,b,c   Kimura, Taichi ^a   Sasai, Ken ^a,d   Wang, Lei ^a   Bizen, Norihisa ^b,c   Nishihara, Hiroshi ^a   Taga, Tetsuya ^b,c   Tanaka, Shinya ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d Kobe MI R and D Center ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CD133 ANTIGEN; MESSENGER RNA; NUCLEAR FACTOR; RAS PROTEIN; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 2; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER STEM CELL; CELL SPECIFICITY; CELL STRAIN CACO 2; CELL TYPE; COLON CARCINOMA; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOCATION; GENE LOCUS; HUMAN; HUMAN CELL; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PROMOTER REGION; SYNOVIAL SARCOMA; ANIMAL; ASTROCYTE; CELL TRANSFORMATION; DOMINANT GENE; DRUG ANTAGONISM; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PROTEIN BINDING; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ASTROCYTES; BINDING SITES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, DOMINANT; GLYCOPROTEINS; HUMANS; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, SCID; NEOPLASTIC STEM CELLS; PEPTIDES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-ETS; RAS PROTEINS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 77649307110     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-39     Document Type: Article

References (59)

1. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768. 10.1038/nrc2499, 18784658.
2. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401. 10.1038/nature03128, 15549107.
3. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951. 10.1158/0008-5472.CAN-05-2018, 16322242.
4. Olempska M, Eisenach PA, Ammerpohl O, Ungefroren H, Fandrich F, Kalthoff H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int 2007, 6:92-97.
5. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007, 120:1444-1450. 10.1002/ijc.22476, 17205516.
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115. 10.1038/nature05384, 17122771.
7. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110. 10.1038/nature05372, 17122772.
8. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007, 43:935-946. 10.1016/j.ejca.2007.01.017, 17320377.
9. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006, 355:1253-1261. 10.1056/NEJMra061808, 16990388.
10. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284. 10.1038/nrc1590, 15803154.
11. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760. 10.1038/nature05236, 17051156.
12. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006, 98:1755-1757.
13. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997, 90:5013-5021.
14. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 2000, 97:14720-14725. 18985, 11121071, 10.1073/pnas.97.26.14720.
15. Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, Johnson JE, Wechsler-Reya RJ. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 2005, 8:723-729. 2377345, 15908947, 10.1038/nn1473.
16. Sagrinati C, Netti GS, Mazzinghi B, Lazzeri E, Liotta F, Frosali F, Ronconi E, Meini C, Gacci M, Squecco R, et al. Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006, 17:2443-2456. 10.1681/ASN.2006010089, 16885410.
17. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004, 117:3539-3545. 10.1242/jcs.01222, 15226377.
18. Kordes C, Sawitza I, Muller-Marbach A, Ale-Agha N, Keitel V, Klonowski-Stumpe H, Haussinger D. CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun 2007, 352:410-417. 10.1016/j.bbrc.2006.11.029, 17118341.
19. Oshima Y, Suzuki A, Kawashimo K, Ishikawa M, Ohkohchi N, Taniguchi H. Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting. Gastroenterology 2007, 132:720-732. 10.1053/j.gastro.2006.11.027, 17258722.
20. Ito Y, Hamazaki TS, Ohnuma K, Tamaki K, Asashima M, Okochi H. Isolation of murine hair-inducing cells using the cell surface marker prominin-1/CD133. J Invest Dermatol 2007, 127:1052-1060. 10.1038/sj.jid.5700665, 17185982.
21. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT, Poppleton H, Zakharenko S, Ellison DW, Gilbertson RJ. Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation. Nature 2009, 457:603-607. 2633030, 19092805, 10.1038/nature07589.
22. Zacchigna S, Oh H, Wilsch-Brauninger M, Missol-Kolka E, Jaszai J, Jansen S, Tanimoto N, Tonagel F, Seeliger M, Huttner WB, et al. Loss of the cholesterol-binding protein prominin-1/CD133 causes disk dysmorphogenesis and photoreceptor degeneration. J Neurosci 2009, 29:2297-2308. 10.1523/JNEUROSCI.2034-08.2009, 19228982.
23. Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X, Rafii S. Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004, 103:2055-2061. 10.1182/blood-2003-06-1881, 14630820.
24. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, Tanino M, Nishihara H, Tanaka S. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 2008, 18:1037-1046. 10.1038/cr.2008.270, 18679414.
25. Sementchenko VI, Watson DK. Ets target genes: past, present and future. Oncogene 2000, 19:6533-6548. 10.1038/sj.onc.1204034, 11175369.
26. Seth A, Watson DK. ETS transcription factors and their emerging roles in human cancer. Eur J Cancer 2005, 41:2462-2478. 10.1016/j.ejca.2005.09.005, 16213704.
27. Sasai K, Akagi T, Aoyanagi E, Tabu K, Kaneko S, Tanaka S. O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies. Mol Cancer 2007, 6:36. 1892783, 17547775, 10.1186/1476-4598-6-36.
28. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403. 10.1016/j.ccr.2006.03.030, 16697959.
29. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem 2000, 275:5512-5520. 10.1074/jbc.275.8.5512, 10681530.
30. Miyazaki J, Takaki S, Araki K, Tashiro F, Tominaga A, Takatsu K, Yamamura K. Expression vector system based on the chicken beta-actin promoter directs efficient production of interleukin-5. Gene 1989, 79:269-277. 10.1016/0378-1119(89)90209-6, 2551778.
31. Akagi T, Sasai K, Hanafusa H. Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. Proc Natl Acad Sci USA 2003, 100:13567-13572. 263854, 14597713, 10.1073/pnas.1834876100.
32. Tabu K, Ohba Y, Suzuki T, Makino Y, Kimura T, Ohnishi A, Sakai M, Watanabe T, Tanaka S, Sawa H. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA. Mol Cancer Res 2007, 5:1099-1109. 10.1158/1541-7786.MCR-07-0096, 17951409.
33. Tabu K, Ohnishi A, Sunden Y, Suzuki T, Tsuda M, Tanaka S, Sakai T, Nagashima K, Sawa H. A novel function of OLIG2 to suppress human glial tumor cell growth via p27Kip1 transactivation. J Cell Sci 2006, 119:1433-1441. 10.1242/jcs.02854, 16554441.
34. Scott GK, Chang CH, Erny KM, Xu F, Fredericks WJ, Rauscher FJ, Thor AD, Benz CC. Ets regulation of the erbB2 promoter. Oncogene 2000, 19:6490-6502. 10.1038/sj.onc.1204041, 11175365.
35. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004, 101:781-786. 321758, 14711994, 10.1073/pnas.0307618100.
36. Puglisi MA, Saulnier N, Sgambato A, Rafanelli F, Barba M, Piscaglia AC, Boninsegna A, Giorda E, Carsetti R, Giuliante F, et al. Tumor-Initiating Cells in Colon Cancer and Liver Metastases: Biological and Molecular Characterization. Dig Liver Dis 2009, 41:S7.
37. Fisher RJ, Mavrothalassitis G, Kondoh A, Papas TS. High-affinity DNA-protein interactions of the cellular ETS1 protein: the determination of the ETS binding motif. Oncogene 1991, 6:2249-2254.
38. Wasylyk C, Maira SM, Sobieszczuk P, Wasylyk B. Reversion of Ras transformed cells by Ets transdominant mutants. Oncogene 1994, 9:3665-3673.
39. Wu C, Alman BA. Side population cells in human cancers. Cancer Lett 2008, 268:1-9. 10.1016/j.canlet.2008.03.048, 18487012.
40. Reynolds BA, Weiss S. Clonal and population analyses demonstrate that an EGF-responsive mammalian embryonic CNS precursor is a stem cell. Dev Biol 1996, 175:1-13. 10.1006/dbio.1996.0090, 8608856.
41. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008, 99:1285-1289. 2570510, 18781171, 10.1038/sj.bjc.6604664.
42. Kojima M, Ishii G, Atsumi N, Fujii S, Saito N, Ochiai A. Immunohistochemical detection of CD133 expression in colorectal cancer: a clinicopathological study. Cancer Sci 2008, 99:1578-1583. 10.1111/j.1349-7006.2008.00849.x, 18754869.
43. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K. Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008, 62:1212-1218. 10.1111/j.1742-1241.2008.01777.x, 18479363.
44. Tong QS, Zheng LD, Tang ST, Ruan QL, Liu Y, Li SW, Jiang GS, Cai JB. Expression and clinical significance of stem cell marker CD133 in human neuroblastoma. World J Pediatr 2008, 4:58-62. 10.1007/s12519-008-0012-z, 18402255.
45. Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma. PLoS ONE 2008, 3:e1936. 2277459, 18398462, 10.1371/journal.pone.0001936.
46. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, Natsugoe S, Aikou T, Takao S. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer 2008, 98:1389-1397. 2361715, 18349830, 10.1038/sj.bjc.6604307.
47. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res 2008, 14:123-129. 10.1158/1078-0432.CCR-07-0932, 18172261.
48. Barker N, Ridgway RA, van Es JH, Wetering M, Begthel H, Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:608-611. 10.1038/nature07602, 19092804.
49. Velden AW, Thomas AA. The role of the 5' untranslated region of an mRNA in translation regulation during development. Int J Biochem Cell Biol 1999, 31:87-106. 10.1016/S1357-2725(98)00134-4, 10216946.
50. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007, 8:286-298. 10.1038/nrg2005, 17339880.
51. Rajalingam K, Schreck R, Rapp UR, Albert S. Ras oncogenes and their downstream targets. Biochim Biophys Acta 2007, 1773:1177-1195. 10.1016/j.bbamcr.2007.01.012, 17428555.
52. Gotoh N. Control of stemness by fibroblast growth factor signaling in stem cells and cancer stem cells. Curr Stem Cell Res Ther 2009, 4:9-15. 10.2174/157488809787169048, 19149625.
53. Armstrong L, Hughes O, Yung S, Hyslop L, Stewart R, Wappler I, Peters H, Walter T, Stojkovic P, Evans J, et al. The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet 2006, 15:1894-1913. 10.1093/hmg/ddl112, 16644866.
54. Sabnis AJ, Cheung LS, Dail M, Kang HC, Santaguida M, Hermiston ML, Passegue E, Shannon K, Braun BS. Oncogenic Kras initiates leukemia in hematopoietic stem cells. PLoS Biol 2009, 7:e59. 2656550, 19296721, 10.1371/journal.pbio.1000059.
55. Guo X, Stratton L, Schrader JW. Expression of activated M-Ras in hemopoietic stem cells initiates leukemogenic transformation, immortalization and preferential generation of mast cells. Oncogene 2006, 25:4241-4244. 10.1038/sj.onc.1209452, 16501601.
56. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3:e2888. 2492808, 18682804, 10.1371/journal.pone.0002888.
57. Lee JS, Gil JE, Kim JH, Kim TK, Jin X, Oh SY, Sohn YW, Jeon HM, Park HJ, Park JW, et al. Brain cancer stem-like cell genesis from p53-deficient mouse astrocytes by oncogenic Ras. Biochem Biophys Res Commun 2008, 365:496-502. 10.1016/j.bbrc.2007.11.005, 18021740.
58. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, Song E. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123. 10.1016/j.cell.2007.10.054, 18083101.
59. Katayama K, Yoshioka S, Tsukahara S, Mitsuhashi J, Sugimoto Y. Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein. Mol Cancer Ther 2007, 6:2092-2102. 10.1158/1535-7163.MCT-07-0148, 17620438.